Definition and epidemiology
COVID-19 is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel betacoronavirus. The World Health Organization declared it a pandemic in March 2020.
Epidemiology:
- Global disease with hundreds of millions of confirmed cases and millions of deaths worldwide since 2019
- Transmission occurs primarily via respiratory droplets and aerosols; fomite transmission is less common
- Incubation period: typically 2-14 days (median 4-5 days)
- Contagious period begins 1-2 days before symptom onset and peaks early in the illness
- All age groups susceptible; children typically have milder disease
- Case fatality rate varies by age, comorbidities, vaccination status, and healthcare access (overall <1% in vaccinated populations, higher in elderly and unvaccinated)
- Variants of concern (Alpha, Beta, Gamma, Delta, Omicron) have emerged with varying transmissibility and immune escape properties
- SARS-CoV-2 enters cells via ACE2 receptor; spike protein is the target of vaccines and neutralizing antibodies.
- Anosmia and ageusia are highly specific symptoms; bilateral ground-glass opacities on CT are characteristic.
- Elevated D-dimer is the single best laboratory predictor of severe disease and thrombotic complications.
- Dexamethasone reduces mortality in patients requiring supplemental oxygen but not in mild disease.
- Cytokine storm (elevated IL-6, ferritin) drives severe disease; tocilizumab or baricitinib added to steroids in severe cases.
- Prophylactic anticoagulation is indicated for all hospitalized COVID-19 patients due to high thrombotic risk.
- RT-PCR is the gold standard for diagnosis; antigen tests have lower sensitivity but faster turnaround.
- Nirmatrelvir-ritonavir reduces hospitalization in high-risk outpatients if started within 5 days of symptom onset.
Etiology and risk factors
Etiology:
SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus. The virus binds to angiotensin-converting enzyme 2 (ACE2) receptors via its spike (S) protein, facilitating cellular entry through endocytosis or membrane fusion. Transmembrane protease serine 2 (TMPRSS2) primes the spike protein for entry.
Risk factors for infection:
- Close contact with infected individuals (household, healthcare, congregate settings)
- Indoor crowded environments with poor ventilation
- Lack of vaccination or prior infection
- Immunosuppression
Risk factors for severe disease:
- Age: ≥65 years (exponentially increased risk with advancing age)
- Chronic medical conditions: cardiovascular disease, diabetes mellitus, chronic kidney disease, chronic lung disease (COPD, asthma), obesity (BMI ≥30), cancer, immunosuppression
- Pregnancy (especially third trimester)
- Smoking
- Male sex
- Certain ethnic minorities (higher rates in some populations, partly due to socioeconomic factors)
- Unvaccinated status
Pathophysiology
SARS-CoV-2 primarily targets the respiratory tract but can affect multiple organ systems due to widespread ACE2 receptor distribution.
Respiratory involvement
Viral replication in respiratory epithelial cells leads to cell death and inflammation. Type II pneumocytes are particularly affected, impairing surfactant production and gas exchange. Severe cases progress to diffuse alveolar damage with hyaline membrane formation, characteristic of ARDS.
Immune dysregulation
Severe COVID-19 features excessive cytokine release ("cytokine storm") with elevated IL-6, IL-1, TNF-α, and interferon-γ. This hyperinflammatory state causes endothelial injury, increased vascular permeability, and multiorgan dysfunction. Lymphopenia is common, reflecting immune exhaustion and lymphocyte sequestration.
Thrombotic complications
Endothelial dysfunction, platelet activation, complement activation, and coagulation cascade activation lead to a hypercoagulable state. Both microvascular thrombosis and large-vessel thromboembolism occur, contributing to organ damage. Elevated D-dimer correlates with disease severity.
Multisystem effects
- Cardiac: Myocardial injury (troponin elevation), myocarditis, arrhythmias, stress cardiomyopathy
- Renal: Acute kidney injury from direct viral invasion, hypoxia, and cytokine-mediated damage
- Neurologic: Anosmia/ageusia (olfactory nerve involvement), encephalopathy, stroke
- Gastrointestinal: Direct viral replication in enterocytes (ACE2-rich)
Post-acute sequelae (Long COVID)
Persistent symptoms beyond 4 weeks may result from viral persistence, immune dysregulation, endothelial dysfunction, or autonomic dysfunction.
Clinical features
COVID-19 presents across a spectrum from asymptomatic to critical illness.
Mild to moderate disease (80-85% of cases):
- Constitutional: Fever, fatigue, myalgia, headache
- Respiratory: Dry cough, sore throat, nasal congestion
- Sensory: Anosmia (loss of smell), ageusia (loss of taste) — highly specific
- Gastrointestinal: Nausea, vomiting, diarrhea (20-30%)
- Symptoms typically resolve within 1-2 weeks
Severe disease (15% of cases):
- Dyspnea, hypoxemia (SpO₂ <94% on room air)
- Tachypnea (respiratory rate >30/min)
- Lung infiltrates >50% on imaging
- Onset typically 5-8 days after symptom onset
Critical disease (5% of cases):
- ARDS: Severe hypoxemia requiring high-flow oxygen or mechanical ventilation
- Septic shock: Hypotension, organ hypoperfusion, lactate elevation
- Multiorgan dysfunction: Acute kidney injury, cardiac injury (elevated troponin), hepatic injury, encephalopathy
- Thrombotic complications: Pulmonary embolism, deep vein thrombosis, stroke, myocardial infarction
Atypical presentations:
- Children and young adults may present with fever and minimal respiratory symptoms
- Multisystem inflammatory syndrome in children (MIS-C): Kawasaki-like presentation 2-6 weeks post-infection
- Elderly may present with delirium, functional decline, or falls without fever
Post-acute COVID-19 syndrome (Long COVID):
Symptoms persisting >4 weeks: fatigue, dyspnea, cognitive dysfunction ("brain fog"), chest pain, palpitations, joint pain. Occurs in approximately 10-30% of infected individuals.
Diagnosis
Clinical diagnosis:
Suspect COVID-19 in patients with compatible symptoms, especially with known exposure. However, clinical features alone cannot reliably distinguish COVID-19 from other respiratory infections.
Virological testing:
- RT-PCR (nucleic acid amplification test): Gold standard; detects viral RNA from nasopharyngeal swab, oropharyngeal swab, or saliva. High sensitivity and specificity. Positive during active infection (typically up to 10-14 days in mild cases, longer in severe disease or immunocompromised)
- Rapid antigen tests: Detect viral proteins; faster (15-30 minutes) but lower sensitivity than PCR, especially in asymptomatic or low viral load cases. Best used in symptomatic patients or high-prevalence settings
- Antibody tests: IgM and IgG serology; indicate prior infection or vaccination, not useful for acute diagnosis
Laboratory findings in severe disease:
- Inflammatory markers: Elevated CRP, ferritin, LDH, IL-6
- Hematologic: Lymphopenia, thrombocytopenia (in severe cases), elevated neutrophil-to-lymphocyte ratio
- Coagulation: Elevated D-dimer (strong predictor of severity), prolonged PT/aPTT in severe cases
- Organ injury markers: Elevated troponin (cardiac), elevated creatinine (renal), elevated transaminases (hepatic)
- Arterial blood gas: Hypoxemia, respiratory alkalosis initially, may progress to metabolic acidosis
Imaging:
- Chest X-ray: Bilateral peripheral infiltrates in moderate-severe disease; may be normal early
- Chest CT: More sensitive; bilateral ground-glass opacities with peripheral and lower lobe predominance are characteristic. Crazy-paving pattern, consolidation in advanced cases
- Imaging not required for diagnosis in mild cases but useful for assessing severity and complications
Risk stratification:
Assess disease severity using clinical criteria (oxygen saturation, respiratory rate, mental status), laboratory markers (D-dimer, CRP, lymphocyte count), and imaging to guide management decisions.
Differential diagnosis
COVID-19 shares clinical features with numerous respiratory and systemic infections:
Viral respiratory infections:
- Influenza: Seasonal pattern, more abrupt onset, can be distinguished by PCR; anosmia less common
- Respiratory syncytial virus (RSV): More common in young children and elderly
- Adenovirus, rhinovirus, human metapneumovirus: Milder upper respiratory symptoms typically
- Other coronaviruses: (229E, OC43, NL63, HKU1) cause common cold symptoms
Bacterial pneumonia:
- Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Legionella pneumophila
- May present with fever, cough, and infiltrates; procalcitonin elevation suggests bacterial etiology
- Co-infection or secondary bacterial pneumonia can occur with COVID-19
Other considerations:
- Pulmonary embolism: Dyspnea, chest pain, hypoxemia; COVID-19 itself increases PE risk
- Acute exacerbation of COPD/asthma: Known respiratory disease, often with trigger
- Heart failure: Orthopnea, paroxysmal nocturnal dyspnea, elevated BNP
- Interstitial lung disease: Chronic progressive dyspnea, diffuse infiltrates
- Sepsis from non-pulmonary source: Identify source of infection
In children with MIS-C:
- Kawasaki disease (younger age, no preceding viral illness)
- Toxic shock syndrome
- Acute rheumatic fever
Multiplex PCR panels can simultaneously test for COVID-19 and other respiratory pathogens.
Management
Management is stratified by disease severity. Guidelines have evolved with emerging evidence.
Mild disease (outpatient)
General measures:
- Isolation for 5-10 days depending on symptoms and test results
- Supportive care: hydration, antipyretics (acetaminophen, NSAIDs), rest
- Monitoring for progression (pulse oximetry if available)
Antiviral therapy:
Consider in high-risk patients (elderly, unvaccinated, immunocompromised, multiple comorbidities) if within appropriate timeframes:
- Nirmatrelvir-ritonavir: Oral protease inhibitor combination; reduces hospitalization/death in high-risk patients; must be started within 5 days of symptom onset; drug interaction screening required (ritonavir is CYP3A4 inhibitor)
- Remdesivir: IV antiviral; outpatient formulation available in some settings; can be used within 7 days of symptom onset
- Molnupiravir: Oral antiviral; less effective than nirmatrelvir-ritonavir, used when alternatives unavailable
Moderate to severe disease (hospitalized)
Supportive care:
- Supplemental oxygen to maintain SpO₂ ≥92-94%
- Prone positioning in non-intubated hypoxemic patients improves oxygenation
- Fluid management: avoid volume overload
- Venous thromboembolism prophylaxis: prophylactic anticoagulation (enoxaparin, heparin) for all hospitalized patients unless contraindicated
Pharmacologic therapy:
- Corticosteroids: Dexamethasone (or equivalent) is the cornerstone for patients requiring supplemental oxygen; reduces mortality. Not recommended in mild disease without hypoxemia
- Remdesivir: IV antiviral; benefit primarily in patients requiring low-flow oxygen, less clear in mechanical ventilation
- Tocilizumab or baricitinib: IL-6 inhibitor or JAK inhibitor added to corticosteroids in patients with rapidly increasing oxygen needs and elevated inflammatory markers
Advanced respiratory support:
- High-flow nasal cannula (HFNC) or non-invasive ventilation (NIV) for persistent hypoxemia
- Mechanical ventilation with lung-protective strategies (low tidal volume 4-6 mL/kg ideal body weight) if ARDS develops
- Extracorporeal membrane oxygenation (ECMO) in refractory ARDS at specialized centers
Critical care
- ICU-level monitoring and organ support
- Vasopressors for shock (norepinephrine first-line)
- Renal replacement therapy for acute kidney injury
- Therapeutic anticoagulation may be considered in selected patients with high thrombotic risk and low bleeding risk
Therapies NOT routinely recommended
- Hydroxychloroquine, ivermectin, azithromycin (without bacterial co-infection), convalescent plasma (outside clinical trials): insufficient evidence or shown ineffective
Prevention
- Vaccination: Most effective prevention strategy; mRNA vaccines (BNT162b2, mRNA-1273) and other platforms reduce infection, severe disease, and death
- Infection control: Masks in healthcare settings and crowded indoor spaces, hand hygiene, physical distancing
- Post-exposure prophylaxis: Antiviral therapy or monoclonal antibodies in high-risk exposed individuals (availability varies)
Long COVID management
Multidisciplinary approach: symptom-directed treatment, rehabilitation, gradual return to activity. No specific pharmacologic therapy proven effective.
Complications and prognosis
Acute complications:
- ARDS: Most common severe complication; mortality 30-50% depending on severity and supportive care
- Septic shock and multiorgan failure: High mortality
- Thrombotic complications: Pulmonary embolism (5-20% of hospitalized patients), deep vein thrombosis, stroke, myocardial infarction
- Cardiac: Myocarditis, arrhythmias, heart failure, takotsubo cardiomyopathy
- Acute kidney injury: Occurs in 20-40% of hospitalized patients, may require dialysis
- Secondary bacterial or fungal infections: Ventilator-associated pneumonia, invasive aspergillosis, candidemia
- Neurologic: Encephalopathy, stroke, seizures, Guillain-Barré syndrome (rare)
- Multisystem inflammatory syndrome: MIS-C in children, MIS-A in adults (rare)
Long-term complications (Long COVID):
- Persistent symptoms in 10-30% of infected individuals
- Fatigue, dyspnea, cognitive impairment most common
- Postural orthostatic tachycardia syndrome (POTS)
- Persistent lung abnormalities (organizing pneumonia, fibrosis)
- Increased risk of cardiovascular events in the year following infection
Prognosis:
Overall mortality: <1% in vaccinated populations; varies widely by age, vaccination, comorbidities, and healthcare access
Mortality by age (unvaccinated):
- <50 years: <0.5%
- 50-69 years: 1-3%
- ≥70 years: 5-15%
Favorable prognostic factors:
- Young age
- Absence of comorbidities
- Vaccination
- Mild symptoms
- Normal oxygen saturation
- Low inflammatory markers
Poor prognostic factors:
- Advanced age (especially >75 years)
- Multiple comorbidities
- Immunosuppression
- Severe hypoxemia (requiring mechanical ventilation)
- Markedly elevated D-dimer, ferritin, IL-6, or LDH
- Lymphopenia
- Elevated troponin or creatinine
Recovery:
Most patients with mild disease recover fully within 2 weeks. Hospitalized patients may require weeks to months for full recovery. Some patients with severe ARDS have persistent pulmonary impairment. Long COVID symptoms may persist for months to years; natural history still being defined.
Reinfection:
Possible, especially with new variants, but typically milder than initial infection in immunocompetent individuals. Vaccination reduces reinfection risk.
COVID ARDS for severe disease features: Cytokine storm, Oxygen requirement, Venous thromboembolism risk, Inflammatory markers elevated, D-dimer elevated, ACE2 receptor entry, Respiratory failure, Dexamethasone benefit, Spike protein target.
Practice questions
1. A 68-year-old man with type 2 diabetes presents to the emergency department with 7 days of fever, dry cough, and progressive dyspnea. He is hypoxemic with SpO₂ 88% on room air. Chest X-ray shows bilateral infiltrates. Laboratory results: lymphocyte count 600/µL, D-dimer 1200 ng/mL, CRP 150 mg/L, ferritin 800 ng/mL. RT-PCR is positive for SARS-CoV-2. In addition to supplemental oxygen and prophylactic anticoagulation, which of the following is the most appropriate pharmacologic treatment?
2. A 45-year-old unvaccinated woman presents to her primary care physician with 2 days of fever, myalgia, and loss of smell. She has a history of obesity (BMI 35) and hypertension. RT-PCR confirms SARS-CoV-2 infection. Oxygen saturation is 96% on room air. Which of the following is the most appropriate management?
3. A 72-year-old man hospitalized with COVID-19 pneumonia develops sudden-onset dyspnea and chest pain on hospital day 5. He is receiving supplemental oxygen, dexamethasone, and prophylactic enoxaparin. Vital signs: temperature 37.8°C, heart rate 110/min, blood pressure 120/75 mmHg, respiratory rate 28/min, SpO₂ 89% on 4L nasal cannula. Which of the following laboratory findings would most strongly support the suspected diagnosis?
Frequently asked questions
What causes COVID-19?
COVID-19 is caused by SARS-CoV-2, a novel coronavirus that emerged in late 2019. The virus spreads primarily through respiratory droplets and aerosols when an infected person coughs, sneezes, talks, or breathes. It enters human cells by binding to ACE2 receptors found on respiratory epithelial cells and other tissues. Transmission occurs most efficiently indoors and in crowded settings with poor ventilation. The incubation period is typically 2-14 days, with a median of 4-5 days.
What are the first symptoms of COVID-19?
The most common early symptoms are fever, dry cough, and fatigue, typically appearing 4-5 days after exposure. Many patients also experience loss of smell (anosmia) or taste (ageusia), which are highly specific for COVID-19. Other early symptoms include headache, sore throat, muscle aches, and nasal congestion. Some patients develop gastrointestinal symptoms like diarrhea, nausea, or vomiting. About 20-40% of infections are asymptomatic. Symptoms in severe cases progress to shortness of breath and hypoxemia around 5-8 days after onset.
How is COVID-19 diagnosed?
COVID-19 is diagnosed primarily through RT-PCR testing, which detects viral RNA from a nasopharyngeal or nasal swab and is the most accurate test. Rapid antigen tests are faster but less sensitive and work best in symptomatic patients with higher viral loads. Testing is recommended for anyone with symptoms suggestive of COVID-19 or after known exposure. Antibody tests detect past infection but are not useful for diagnosing acute illness. In hospitalized patients, chest imaging (CT showing bilateral ground-glass opacities) and laboratory markers (elevated D-dimer, CRP, ferritin, lymphopenia) help assess severity.
Is COVID-19 curable?
Most people with COVID-19 recover completely within 2 weeks without specific treatment through their immune system clearing the virus. Mild cases are managed with supportive care like rest, hydration, and fever control. High-risk patients may benefit from antiviral medications (nirmatrelvir-ritonavir, remdesivir) if started early. Severe cases require hospitalization with oxygen support and dexamethasone, which reduces mortality. While COVID-19 is not "curable" in the traditional sense, most patients recover fully. However, 10-30% develop long COVID with persistent symptoms. Vaccination is the most effective strategy to prevent severe disease.
COVID-19 vs influenza — what is the difference?
Both are respiratory viruses but differ in several ways. COVID-19 has a longer incubation period (4-5 days vs 1-2 days for flu) and a higher rate of severe disease and death, especially in older adults and those with comorbidities. Loss of smell and taste are much more common with COVID-19. COVID-19 causes more thrombotic complications and has higher rates of long-term symptoms. Both can be prevented by vaccination. Definitive diagnosis requires specific testing (PCR or antigen tests), as symptoms overlap significantly. Treatment differs: antivirals like nirmatrelvir-ritonavir for COVID-19, oseltamivir for influenza.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: U07.1
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.